Treatment of endometrial stromal tumors

• Published in: Gynecologic oncology Vol. 36; no. 1; pp. 60 - 65
• Main Authors: Berchuck, Andrew, Rubin, Stephen C., Hoskins, William J., Saigo, Patricia E., Pierce, Virginia K., Lewis, John L.
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 1990; Elsevier
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Combined Modality Therapy; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Mitosis; Neoplasm Recurrence, Local - therapy; Ovariectomy; Sarcoma - therapy; Survival Rate; Tumors; Uterine Neoplasms - mortality; Uterine Neoplasms - pathology; Uterine Neoplasms - therapy; Human; Sarcoma; Stroma; Malignant tumor; Radiotherapy; Survival; Female genital diseases; Chemotherapy; Treatment; Uterus; Evolution; Female; Tumor; Endometrium
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/0090-8258(90)90109-X

We reviewed 31 cases of endometrial stromal tumors treated on the Gynecology Service at Memorial Sloan-Kettering Cancer Center from 1970 to 1984. Twenty-two patients had endolymphatic stromal myosis and 9 patients had endometrial stromal sarcoma. Twenty-six patients initially had disease confined to the uterus. Following hysterectomy, 7 patients received various adjuvant therapies, but no active adjuvant regimen was identified. All 3 patients who presented with advanced endometrial stromal sarcoma died of rapidly progressive disease; only 2 of 6 patients with stage I endometrial stromal sarcoma developed recurrence. Among patients with endolymphatic stromal myosis, a higher recurrence rate was noted in patients with residual ovarian tissue (100%) than in those without residual ovarian tissue (43%). Fifteen patients were treated for recurrent disease (13 with endolymphatic stromal myosis, 2 with endometrial stromal sarcoma). Following attempts to resect disease surgically, objective responses were attained with both chemotherapy (57%) and radiation (40%). The median survival following treatment of recurrent disease was 46 months. Actuarial survival for all patients in this study was 76% at 5 years and 69% at 10 years.